Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORBIT1: Oral Budesonide Suspension in Eosinophilic Esophagitis
NCT02605837Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2015
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of EPI-EE in eosinophilic esophagitis (EoE), sponsored by Takeda. Started Dec 2015; status: completed.
02
Drugs
EPI-EE
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT02605837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605837.